Amicogen Q3 Consolidated Operating Loss of KRW 13.3B, Asset Restatement Reduces Equity by KRW 7.6B

Financial statement restatement: investment in subsidiaries and associates decreased by KRW 7.6B, reducing equity by the same amount (negative)
Consolidated revenue: KRW 31.1B (down 73% from KRW 116.7B in the same period last year, due to the deconsolidation of the raw material drug business)
Consolidated operating loss: KRW 13.3B (loss widened from KRW 6.2B in the same period last year)
Consolidated net loss: KRW 24.8B (increased from KRW 19.0B loss in the same period last year)
Separate: revenue KRW 29.8B, operating loss KRW 8.6B, net loss KRW 15.5B
Net borrowings: KRW 97.4B, debt ratio 137.4%, net borrowing ratio 96.1%
Early redemption risk on convertible bonds due to loss of maturity benefit (3rd to 6th CBs)
Patent infringement and administrative lawsuits in China ongoing
No share buyback/cancellation or dividend plans